Paroxysmal Atrial Fibrillation Clinical Trial
— VEIN-AFOfficial title:
Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable Pulmonary Vein Isolation
The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might substantially improve long-term outcomes. The aim of this study is to evaluate the recurrence rate 1 year after the index ablation in patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF) despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with substrate modification including vein of Marshal ethanolisation in addition to SVC isolation alone
Status | Recruiting |
Enrollment | 100 |
Est. completion date | August 31, 2023 |
Est. primary completion date | August 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients older than 18 years - Patients scheduled for a repeat ablation of PAF after a previous PVI - Confirmation of lasting pulmonary vein isolation at the time of randomization Exclusion Criteria: - Patients with persistent atrial fibrillation - Previous ablation with isolation of the SVC, roofline, mitral line or previous vein of Marshal ethanol infusion - Left atrial thrombus. Left atrial appendage thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI. - Left ventricular ejection fraction <35%. - Cardiac surgery within the previous 90 days. - Expecting cardiac transplantation or other cardiac surgery within 180 days. - Coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days. - Documented history of a thromboembolic event within the previous 90 days. - Diagnosed atrial myxoma. - Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms. - Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment - Women who are pregnant or who plan to become pregnant during the study. - Acute illness or active infection at time of index procedure - Advanced renal insufficiency - Unstable angina. - History of blood clotting or bleeding abnormalities. - Contraindication to anticoagulation. - Life expectancy less than 1 year. - Presence of a condition that precludes vascular access. - International Normalized Ratio greater than 3.5 within 24 hours of procedure - for patients taking warfarin. - Patient cannot be removed from antiarrhythmic drugs for reasons other than AF. - Unwilling or unable to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
Belgium | AZ Sint-Jan Brugge-Oostende AV | Brugge | Please Select |
Lead Sponsor | Collaborator |
---|---|
AZ Sint-Jan AV |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence of atrial tachyarrhythmia 1 year after the index ablation | Comparison of the prevalence of atrial tachyarrhythmia recurrence 1 year after the index ablation between groups | 1 year | |
Primary | Safety (complications) | Comparison of the number of procedural complications between groups | During procedure | |
Secondary | Total procedural time | Comparison of the procedural time between groups | During procedure | |
Secondary | Fluoroscopy time | Comparison of the fluoroscopy time between groups | During procedure | |
Secondary | RF ablation time | Comparison of the radiofrequency time between groups | During procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT06014996 -
Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.
|
N/A | |
Completed |
NCT03624881 -
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
|
Phase 4 | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Recruiting |
NCT05905835 -
Treatment of PAF With the Synaptic System
|
N/A | |
Active, not recruiting |
NCT05618340 -
PFA for Paroxysmal Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT05534581 -
SINGLE SHOT CHAMPION
|
Phase 4 | |
Not yet recruiting |
NCT05024630 -
Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension
|
N/A | |
Completed |
NCT01913522 -
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration
|
N/A | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Terminated |
NCT01925885 -
Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
|
N/A | |
Withdrawn |
NCT01917981 -
Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation
|
Phase 3 | |
Completed |
NCT01842529 -
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01693107 -
Atrial Fibrillation Force Contact Ablation Study
|
||
Completed |
NCT00971204 -
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Recruiting |
NCT05172765 -
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Completed |
NCT00964392 -
NAVISTAR® THERMOCOOL® Catheter Post Approval Registry
|
Phase 4 | |
Recruiting |
NCT03912324 -
Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)
|
N/A |